Loading market dashboard
Eli Lilly and Company
LLYHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Eli Lilly leads three health care stocks to watch as the market appears to be rotating into medicals. Google stock is finding key support too.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
UnitedHealth Group (UNH, Financials) and Eli Lilly (LLY, Financials) are emerging as leaders in a renewed healthcare sector rally as investors increasingly rota
The seasonal strength lines up with major medical and scientific conferences that cluster during this period.
Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum.
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Eli Lilly (LLY, Financials) plans to scale back its investment in Germany, reducing a previously announced â¬2.3 billion commitment by roughly half as concerns
L
Eli Lilly has worked hard to diversify its pipeline. Three new acquisitions will further help decrease its exposure to its core market.
Over recent months, a striking pattern has emerged: major capital allocators are positioning around AI-driven biology and longevity.
Eli Lilly (NYSE:LLY | LLY Price Prediction) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion.
This particular sector may suit cautious and aggressive investors.
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its gene-editing technology with pharma major Eli Lilly , worth up to $1.9 billion, to develop new therapies for rare inherited kidney diseases.
Eli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate. It could compete with CRISPR Therapeutics, a gene editing-focused biotech.
Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL will be highlighted in a late-breaking oral presentation Ajax Therapeutics, which Lilly has agreed to acquire, will present the first clinical data for its first-in-class type II JAK2 inhibitor for patients with myelofibrosis who have been failed by a type I JAK2 inhibitor Kelonia Therapeutics, which Lilly has agreed to acquire, will present additional correlative clinical data for its in vivo CAR-T program in patients with multiple myeloma INDIANAPOLIS, June 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the details of presentations at the European Hematology Association (EHA) Annual Meeting, taking place June 11-14 in Stockholm, Sweden. Data to be highlighted include an oral presentation detailing results from the Phase 3 BRUIN CLL-322 study of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, as part of a time-limited regimen for patients with previously treated chronic lymphocytic leukemia (CLL).
The June 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading ~30% below intrinsic value, with a 1.50% average yield and 17.61% five-year dividend growth. I estimate a compelling +21% long-term annual return for this basket, driven by strong dividend growth and fundamental business expansion. Standouts include Nvidia for projected growth, Eli Lilly for recent outperformance, and Accenture for high yield, with custom yield theory valuations guiding selection.
David Ricks was addressing the pharmaceutical titan's latest hot product.
Macro strategist Jordi Visser delivered a striking observation on a recent episode of The Pomp Podcast with Anthony Pompliano.
U.S. drugmaker Eli Lilly has entered into an agreement to collaborate on and possibly licence experimental medicines from a unit of Haisco Pharmaceutical Group , with potential payments of up to around $3 billion if milestones are met, the Chinese drugmaker said Monday.
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with ea
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease These data will be published in the New England Journal of Medicine and simultaneously presented during the Plenary Session at the 2026 ASCO Annual Meeting INDIANAPOLIS, May 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) with selpercatinib reducing the risk of disease recurrence or death by 83% versus placebo in the primary analysis population.
At quarter end, Invesco Summit Fund's largest overweights were in industrials, energy and communication services. Within industrials and energy, AI related energy demand has continued to drive spending on electrical infrastructure and power generation. The largest underweight was consumer discretionary, reflecting higher inflation from the US/Israel war with Iran and potential AI related employment pressure.
Eli Lilly stock has climbed in the triple-digits in recent years and just topped $1,000. The company is firing on all cylinders in the high-growth weight loss drug market.
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
Eli Lilly (LLY) is getting a major access win in the obesity drug market after CVS Health reversed its earlier restriction on Zepbound across certain drug plans
Eli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Eli Lilly continues strong execution, exceeding revenue expectations and expanding its pipeline with strategic, low-risk acquisitions in infectious diseases and other areas. LLY's infectious disease deals offer long-term upside, notably with amezosvatein showing superior tolerability to Shingrix, but meaningful revenues are unlikely before 2030. Retatrutide's phase 3 results raise the efficacy bar for obesity drugs, though tolerability issues may limit its uptake versus the better tolerated tirzepatide.
Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.
CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option for insurance coverage.
CVS Health said it will restore coverage of Eli Lilly's blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans. The move supports Lilly's efforts to maintain its dominance over Novo Nordisk in the blockbuster weight loss drug market, as it puts the two drugmakers on equal footing on major drug plans.
CVS Caremark begins covering Foundayo June 1 and resumes Zepbound coverage by October 1 Eligible patients may pay as low as $25 a month for their medicine INDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an access milestone in obesity care: all three of the nation's largest pharmacy benefit managers (PBMs) will cover Lilly's full obesity medicine portfolio. This significantly expands the number of Americans who can access FDA-approved options through their existing insurance.
Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.
Eli Lilly's fundamentals matter more than Trump's stock purchases.
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
INDIANAPOLIS, May 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, will take part in a fireside chat at 3:20 p.m.
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Eli Lilly agreed to acquire Bothell, Wash.
The artificial intelligence (AI) boom continues to set the direction for global financial markets in 2026, but Goldman Sachs strategists argue that opportunities exist outside this tech narrative as well. Concentrated leadership in the AI trade has propelled US benchmark indices to record levels this year, prompting concerns that the current environment resembles a single trade rather than a diversified market.
The pharma company is booming due to innovative treatments.
Eli Lilly (LLY) is stepping back into infectious diseases with a three-deal vaccine push worth as much as $3.8 billion, giving investors another signal that the
Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease prevention. The deals mark a strategic push for Lilly into vaccine development, an area the company said aligns with its broader goal of addressing major global health challenges beyond its core diabetes and obesity portfolio, which has been a key driver of recent cash flow.
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity drugs to expand into other disease areas.
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking's VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not... If Viking Therapeutics Is Acquired, Here's Who Wins
Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in...
The deals are part of Eli Lilly's effort to expand into infectious disease research and development. Shares edged higher in premarket trading on the news.
Agreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treat Acquisitions build on Lilly's infectious disease legacy and reinforce its commitment to prevention strategies that reduce the long-term burden of serious disease INDIANAPOLIS, May 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development efforts into infectious disease. The transactions advance Lilly's strategy of investing in differentiated technology platforms to address significant health problems.
The weight-loss drug market leader is renewing a focus on infectious-disease prevention.
Eli Lilly and Co (NYSE:LLY) last week reported late-stage weight loss data for retatrutide, which UBS analysts highlighted showed “solid strong weight loss efficacy” and were broadly in line with expectations ahead of further detail at the American Diabetes Association meeting. UBS highlighted that the Phase III data in obesity showed a clear dose-response across 4mg to 12mg, with the highest dose producing about 28% weight loss at 80 weeks in patients with a body mass index (BMI) of 30 or higher.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its p
In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular disease VERVE-102 is designed to mimic the protective effect of naturally occurring loss-of-function variants in PCSK9, which are associated with markedly lower lifetime risk of coronary heart disease Lilly plans to begin enrolling the Phase 2 clinical study of VERVE-102 by the end of this year INDIANAPOLIS, May 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein cholesterol (LDL-C) following a single infusion. The Heart-2 trial is evaluating VERVE-102 in adults with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD).
Eli Lilly and Novo Nordisk have been vying for dominance in the weight loss drug market. Lilly has gradually surpassed Novo Nordisk, and it now holds 60% of the U.S. market.
Innovation, regulatory policy, and demographics are driving healthcare stocks higher. Healthcare companies have also posted strong first-quarter results.
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program Investigator-initiated study of Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma also selected for the Plenary Session Kelonia Therapeutics, which Lilly has agreed to acquire, will present updated data for its BCMA-targeted in vivo CAR-T therapy in patients with relapsed and refractory multiple myeloma Additional Lilly presentations include the first clinical results for an investigational ADC targeting Nectin-4 in patients with advanced urothelial carcinoma and data from programs across lung, breast and blood cancers INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the details of presentations from across its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2 in Chicago, Illinois. Data at ASCO include two Plenary Session presentations, featuring primary event-free survival results from the Phase 3 LIBRETTO-432 study of adjuvant Retevmo (selpercatinib) in rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) and an investigator-initiated Phase 3 study, SARC041, evaluating Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma.
